Mazdutide

Compound Overview

Mazdutide (IBI362) is a dual-acting peptide studied for activation of both GLP-1 and glucagon receptors. While Tirzepatide is categorized as a GIP/GLP-1 agonist, Mazdutide combines GLP-1 signaling with glucagon receptor agonism, creating a distinct research model for examining hepatic energy expenditure and fat oxidation pathways in controlled laboratory systems.

Research Background & Published Literature

Mazdutide was developed by Innovent Biologics and Eli Lilly. Published Phase 2/3 clinical trial literature in Lancet Diabetes & Endocrinology has increased research attention on dual GLP-1/glucagon signaling as a mechanistic approach separate from GIP/GLP-1 combination research.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Ji et al. (2025) — N Engl J Med
• Zhang et al. (2024) — Diabetes Care
• Ji et al. (2022) — EClinicalMedicine

Storage, Handling & Stability Guidelines

Store lyophilized Mazdutide at -20°C for long-term stability. After reconstitution with sterile diluent, keep material refrigerated at 2–8°C and reduce freeze-thaw exposure by aliquoting working volumes according to your laboratory's standard operating procedures.

• Keep time at ambient temperature as short as practical during handling to support compound integrity.
• Reseal vials promptly after each withdrawal to limit moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.

Lab Verification

Nexus maintains batch-level verification records for research compounds in the Lab Verified archive, including HPLC purity review and Mass Spectrometry identity confirmation where current lot data is available.